Mon.Jul 08, 2024

article thumbnail

Lilly's Mounjao triggers more weight loss than Novo Nordisk's Ozempic: study

Fierce Pharma

Is Eli Lilly’s Mounjaro or Novo Nordisk’s Ozempic more effective in helping patients lose weight? | Is Eli Lilly’s Mounjaro or Novo Nordisk’s Ozempic more effective in helping patients lose weight? While a head-to-head trial pitting the two treatments remains ongoing, new evidence shows that Lilly’s tirzepatide may be the superior weight loss product.

Patients 317
article thumbnail

A No-Go for HilleVax as Norovirus Vaccine Fails Mid-Stage Test in Infants

MedCity News

HilleVax’s norovirus vaccine failed a Phase 2b study in infants, but it’s not the end of the road for the biotech. A business deal this year brought HilleVax a Phase 1-ready norovirus vaccine candidate designed to offer even broader protection. The post A No-Go for HilleVax as Norovirus Vaccine Fails Mid-Stage Test in Infants appeared first on MedCity News.

Biopharma 104
Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

article thumbnail

Merck puts 1,000-plus Zostavax lawsuits to bed after plaintiffs file for dismissal

Fierce Pharma

After a drawn-out litigation process, Merck & Co. seems to have finally washed its hands of more than a thousand lawsuits tied to its shingles vaccine Zostavax. | A U.S. appeals court has tossed a request to resurrect certain lawsuits claiming Merck’s popular shot Zostavax caused patients to develop shingles. The court made its decision after the plaintiffs filed a voluntary dismissal some two years after logging a loss in Pennsylvania.

Patients 268
article thumbnail

How Can Hospitals Best Leverage Multi-Cancer Screening Tests? Providence Researchers Aim to Find Out

MedCity News

Providence recently launched a study to help learn more about how health systems can use multi-cancer detection tests in clinical care. Three years ago, Providence became the first health system to use Grail’s Galleri test, which screens patients for more than 50 kinds of cancer. The post How Can Hospitals Best Leverage Multi-Cancer Screening Tests?

Patients 104
article thumbnail

AI Strategies for Sales Managers: How to Cut Down on Tedious Admin Work

What if you could help your sellers stop wasting 72% of their day on non-selling activities and focus on bringing in revenue? Incorporating AI in your enablement workflows can help you cut down on busy work, get projects done faster, and let your team (and you!) focus on making a bigger impact. We put together this guide to show you how to use AI to cut time and costs for projects, including collateral creation, development of training videos, and automating tedious processes.

article thumbnail

CDMO Lotte breaks ground on $3.3B production plant in Korea, touts growth goals

Fierce Pharma

After announcing plans last year to expand manufacturing in its home country, Korean CDMO newcomer Lotte Biologics has kicked off work on a sprawling facility along Incheon’s waterfront near Seoul. | Late last week, Lotte Biologics broke ground on its flagship facility at the Songdo Bio Campus in Incheon International City, South Korea. The company is pitching the production effort as a key part of its quest to become one of the top 10 CDMOs in the world.

article thumbnail

Cleanroom microbiology: single-temperature incubation for EM

European Pharmaceutical Review

Single- or mono-temperature incubation is not easy to implement, but it offers efficiency and performance advantages and an opportunity to simplify the process in a pharmaceutical microbiology laboratory. This article shares our motivations, approach and experience of implementing mono-temperature incubation in our laboratories over the past several years.

More Trending

article thumbnail

Myricx Bio gains $114m in Series A round to develop NMTi-ADCs

Pharmaceutical Technology

Myricx Bio has secured £90m ($114m) in its Series A financing round to propel its NMTi-ADC therapeutics into the clinical development stage.

105
105
article thumbnail

Roche to reintroduce eye implant med Susvimo 2 years after recall

Fierce Pharma

Roche's launch of eye implant Susvimo was stopped short in 2022 after manufacturing concerns led to a market withdrawal. Now, with the FDA’s blessing to reintroduce the therapy, the | The company is reintroducing the therapy after receiving the FDA's blessing for updates made to the device, ending a two-year voluntary recall.

article thumbnail

The Syringe Recall: A Case for Improved Recall Communications

MedCity News

There is an urgent need for a universal electronic platform for recall communications. The post The Syringe Recall: A Case for Improved Recall Communications appeared first on MedCity News.

article thumbnail

With Boehringer ruling, industry extends legal losing streak against Medicare price negotiations

Fierce Pharma

As the process surrounding Medicare's drug price negotiations rolls on this summer—and as the pharmaceutical industry continues to loudly voice its complaints—another lawsuit contesting the legal v | Boehringer Ingelheim joins AstraZeneca, J&J and Bristol Myers Squibb in having a case challenging Medicare price negotiations fail to bear fruit.

article thumbnail

From Diagnosis to Delivery: How AI is Revolutionizing the Patient Experience

Speaker: Simran Kaur, Founder & CEO at Tattva Health Inc.

The healthcare landscape is being revolutionized by AI and cutting-edge digital technologies, reshaping how patients receive care and interact with providers. In this webinar led by Simran Kaur, we will explore how AI-driven solutions are enhancing patient communication, improving care quality, and empowering preventive and predictive medicine. You'll also learn how AI is streamlining healthcare processes, helping providers offer more efficient, personalized care and enabling faster, data-driven

article thumbnail

AI Enhancing Multidisciplinary Care in the Autism and IDD Community

MedCity News

Care coordination is complex, but if done effectively, it can positively impact both the learner and the professionals delivering care. The post AI Enhancing Multidisciplinary Care in the Autism and IDD Community appeared first on MedCity News.

94
article thumbnail

Roche scores FDA nod for prefilled syringe version of Vabysmo, easing its administration

Fierce Pharma

Since Roche gained approval for its eye disease medication Vabysmo in 2022, it has stormed a market dominated by Regeneron and Bayer’s Eylea. | Since Roche gained approval for its eye disease medication Vabysmo in 2022, it has stormed a market dominated by Regeneron and Bayer’s Eylea. Roche has taken another step in its advancement of the blockbuster medicine, scoring an FDA nod to provide it in a prefilled syringe.

FDA 239
article thumbnail

Lilly scores against Novo Nordisk in weight loss contest

pharmaphorum

An observational study has suggested that Lilly’s tirzepatide is better at achieving weight loss than Novo Nordisk's semaglutide

111
111
article thumbnail

J&J's tuberculosis med Sirturo lands full US, EU approvals after more than a decade on the market

Fierce Pharma

It took many years, but Johnson & Johnson’s tuberculosis med Sirturo can finally claim full approvals in the U.S. and Europe following initial conditional nods. | The traditional approvals follow initial accelerated approvals granted by the FDA in 2012 and the European Commission in 2014.

Marketing 227
article thumbnail

How to Prove Marketing Value: Demonstrate Content ROI and Contribution to Sales

Every marketer knows how important it is to prove their efforts drive sales opportunities, but that’s easier said than done. When problems like sales and marketing misalignment, lack of data, and wasted efforts persist, marketers can’t measure, prove, or increase their impact on revenue at a time when demonstrating marketing value is critical. Using analyst and expert data, this guide to marketing impact and content attribution explains: How B2B buyers use content The most common types of conten

article thumbnail

Report: Covid-19 Policy Changes Made Healthcare More Affordable

MedCity News

Several policy changes, including the Medicaid continuous enrollment provision and enhanced Marketplace tax credits, improved health coverage and access during Covid-19, a new report showed. The post Report: Covid-19 Policy Changes Made Healthcare More Affordable appeared first on MedCity News.

article thumbnail

Lilly bolsters IBD portfolio with $3.2bn Morphic acquisition

Pharmaceutical Technology

Morphic’s lead asset MORF-057 is being investigated in three IBD clinical trials, with data in ulcerative colitis expected next year.

Leads 98
article thumbnail

Myricx raises £90m after pivot to ADCs for cancer

pharmaphorum

Myricx Bio taps into the red-hot interest in companies working on antibody-drug conjugates (ADCs) for cancer, raising £90m in its Series A

111
111
article thumbnail

GSK and MVV launch malaria medicine in Brazil and Thailand

Pharmaceutical Technology

GSK and MMV have announced the launch of tafenoquine to prevent the relapse of P. vivax malaria in Brazil and Thailand.

Medicine 102
article thumbnail

Optimizing Clinical Supply Strategy: Navigating Challenges & Finding Your Ideal Model

article thumbnail

Study finds GLP-1 drugs may cut obesity-related cancers

pharmaphorum

GLP-1 agonists like Novo Nordisk's Ozempic reduce the risk of 10 of 13 cancers associated with obesity in an observational study.

114
114
article thumbnail

Eli Lilly Shows Appetite for Oral Immunology Drugs, Swallowing Morphic in $3.2B Deal

MedCity News

Eli Lilly’s Morphic acquisition brings an oral small molecule that blocks the same target as Entvyio, an injectable inflammatory bowel disease drug from Takeda Pharmaceutical. The Morphic deal follows Lilly’s 2023 acquisition of Dice Therapeutics, another company developing oral immunology medications. The post Eli Lilly Shows Appetite for Oral Immunology Drugs, Swallowing Morphic in $3.2B Deal appeared first on MedCity News.

Medical 68
article thumbnail

As IARC uprates talc cancer risk, will J&J be affected?

pharmaphorum

IARC has published a new assessment of talc’s potential to cause cancer, concluding that is it ‘probably carcinogenic’ to humans

105
105
article thumbnail

Coloplast launches digital leakage notification system Heylo for stoma patients

PharmaTimes

More than 176,000 people in the UK are living with a stoma, according to NHS data

Patients 102
article thumbnail

Increase Revenue With Better, Faster Sales Onboarding

Quotas need to be hit. Revenue goals need to be met. This reality makes shortening sales onboarding time a top priority. Organizations with a standard onboarding process boost employee retention by 58% and increase productivity by 50%. Unfortunately, many companies struggle with inefficient processes that lead to high turnover and missed revenue opportunities.

article thumbnail

Could Spain’s Grifols be heading for de-listing?

pharmaphorum

The family that owns Spanish pharma Grifols and private equity firm Brookfield may take the company private in a deal worth around €5.

Pharma 103
article thumbnail

Lessons from Lions: EVERSANA INTOUCH Takes on Cannes 

Eversana Intouch

For 70 years, the Cannes Lions International Festival of Creativity showcases the best of the best of the world’s advertising and creative communications. Moreover, it interrogates what good creative is, and what it could be. This year, EVERSANA INTOUCH took a small but intrepid band to Cannes to gather insight. Among them, to our pride, were Susan Perlbachs, Chief Creative Officer at EVERSANA INTOUCH, was a member of the Cannes Lions Health 2024 Pharma Jury, chosen with another 9 peers from aro

Pharma 59
article thumbnail

Lilly swoops on Morphic to claim IBD drug candidate

pharmaphorum

Eli Lilly boosts its inflammatory bowel disease pipeline with a $3.

111
111
article thumbnail

Mission awarded $5.2m to advance potential Parkinson’s treatment

PharmaTimes

The progressive neurodegenerative condition affects around 153,000 people in the UK

81
article thumbnail

European Clinical Supply Planning: Balancing Cost, Flexibility and Time

article thumbnail

The FDA pushes concrete plans to further diversity in clinical trials

PharmaVoice

The long-awaited guidance offers a more detailed road map for pharma.

Pharma 119
article thumbnail

The Nexus between patient and big pharma: Patient-centricity considerations for CDMO and CRO collaborations in novel drug development

PharmaTech

The concept of patient centricity is gaining significant traction in the pharmaceutical industry, reshaping the way drugs are developed and produced. This report, developed in partnership with CPHI, specifically explores how optimizing the pharmaceutical supply chain can help improve patient-centricity, and showcases examples of it already being implemented at large.

article thumbnail

FDA Approves Genentech’s Vabysmo to Treat Wet Age-Related Macular Degeneration, Diabetic Macular Edema, Macular Edema Following Retinal Vein Occlusion

PharmExec

The Vabysmo prefilled syringe is designed to simplify administration for retina specialists, improving the treatment experience for both physicians and patients with wet age-related macular degeneration, diabetic macular edema, and macular edema following retinal vein occlusion.

article thumbnail

UK pharma group reprimands Novo Nordisk for undisclosed payments

Pharmaceutical Technology

The Association of the British Pharmaceutical Industry (ABPI) also called out Novartis, Pfizer, and Otsuka for breaching its code.

Pharma 59
article thumbnail

Using Generative AI in Sales: Pros, Cons, and Considerations According to Sellers

Are your sellers unsure about using AI in their day-to-day workflows? Or are they eager to try but uncertain where to start? They might be asking: Which tasks are best suited for AI? How will using AI affect my relationship with my customers? With so many tools available, which ones are the most useful to me? To help answer these and other common questions about using AI during the sales cycle, we surveyed B2B sellers who were early adopters to get their insight and advice about how to use gen A